Abstract: An air flow sensor comprises a flexible resistive element permanently affixed to a flexible substrate. The air flow sensor is positioned in an inlet for airway to be monitored such that the sensor covers the inlet at all times other than during inhalation. When a vacuum is applied to the airway, a resulting drop in air pressure within the airway causes air to flow through the inlet and airway, causing the sensor's substrate to flex. Flexure of the substrate also causes a resistive element to flex, resulting in a change in the electrical resistance of the resistive element, such as an increase in resistance. Flexure of the sensor is enhanced by flexible leads, which serve as a hinge point. An air shield may be positioned around the periphery of the air flow sensor to channel and restrict the movement of air flowing through the air inlet, thereby enhancing movement of the sensor.

Abstract: Described are heat stable aqueous solutions or gels comprising a biologically effective amount of a protein and an effective stabilizing amount of a polysaccharide gum as well as heat stable solutions or gels suitable for use in an implantable drug delivery device at body temperature. Also disclosed are lyophilized compositions having biologically activity, where such lyophilized compositions are formed by lyophilizing the stabilized solutions or gels of the invention.

Abstract: A composition used in combination with an electrohydrodynamic device capable of delivering an active ingredient to the aerodigestive system of the user. The composition comprises three or optionally four basic components: an active ingredient; a carrier material in which the active ingredient may be dissolved, suspended, or emulsified; an aerosol properties adjusting material which provides the composition with the physical characteristics required to create an aerosol cloud by electrostatic or electrohydrodynamic means; and optionally at least one excipient that further adjusts, preserves, stabilizes, or enhances the overall performance of the composition.

Abstract: A formulation and method for treating neoplasms such as cancer by administering a pharmaceutically effective amount or carboplatin by inhalation.

Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

Abstract: This invention relates to a process for encapsulation, and particularly to the production of small or minute capsules constituted by a skin or thin wall of polymeric material e.g., polyurea, polyamide, polysulfonamide, polyester, polycarbonate, or polyurethane, which involves first providing an aqueous solution (continuous phase liquid) containing an emulsifier which is a water soluble, alkylated polyvinyl pyrrolidone polymer which will form a stable oil-in-water emulsion under the process conditions described herein. A discontinuous (immiscible or organic) phase liquid containing a water-immiscible material which is the material to be encapsulated, plus a first shell wall component; is dispersed in the aqueous liquid to form an oil-in-water emulsion. The second shell wall component is added to the oil-in-water emulsion whereupon the first shell wall component reacts with the second shell wall component to form a solid polycondensate shell wall about the material to be encapsulated.

Abstract: Carbamic acid esters of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, X, and Y are as defined hereinafter, process for their preparation, as well as pesticidal compositions containing these compounds as the active ingredient and methods for using the pesticidal compositions for the control of pests are described.

Abstract: A new biologically active polypeptide hormone has been isolated from calf thymosin fraction 5 and has been given the designation thymosin alpha.sub.11. The peptide contains seven additional amino acid residues at the carboxy terminus when compared to thymosin alpha.sub.1. Thymosin alpha.sub.11 is one of several peptides present in thymosin fraction 5 which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide is approxomately 16 times as potent in the protection of subject animals against opportunistic infections as thymosin fraction 5 and approximately equal in potency to thymosin alpha.sub.1.

Abstract: There are described novel porphyrin derivatives of the general formula ##STR1## wherein either R.sup.1 signifies the group ##STR2## and R.sup.2 signifies the group ##STR3## or R.sup.1 signifies the group ##STR4## and R.sup.2 signifies the group ##STR5## whereby X.sup.- signifies a halogen ion, an arylsulphonate ion, an alkylsulphonate ion or an alkyl sulphate ion, A signifies (C.sub.1-8)-alkylene and R.sup.3 signifies (C.sub.1-4)-alkyl,and sulphonic acid salts of compounds of formula I in which R.sup.1 signifies the group ##STR6## as well as a process for their manufacture and intermediates used in this process.Because of their water-solubility the novel porphyrin derivatives are suitable as label molecules for highly sensitive fluorescence immuno-assays, especially for time-resolving fluorescence immuno-assays. The coupling of the novel porphyrin derivatives to immunologically-active materials is carried out in the customary manner, for example with a water-soluble carbodiimide derivative.

Abstract: A method of producing analgesia by administering an opiate alkaloid such as morphine, codeine, oxycodone or a pharmaceutically acceptable acid addition salt thereof together with a carbazole compound, 6-chloro-.alpha.-methyl-carbazole-2-acetic acid, or a salt thereof with a pharmaceutically acceptable base and composition therefor.

Abstract: A process for the preparation of the .beta.' form of the copper chelate of 8-hydroxyquinoline (copper oxinate), stabilized compositions containing said chelate, fungicidal compositions containing said chelate, and the methods for using said .beta.' form chelate or compositions for combatting fungi are disclosed.

Abstract: Novel vasoactive intestinal peptide analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule, with potent sustained bronchodilatory activity without cardiovascular side effects.

Abstract: A catalytic synthesis of chromans in racemic or optically active forms, including intermediates thereto; the synthesis employs an asymmetric palladium (II) catalyzed oxidative cyclization of a 2-homoallylphenol and provides intermediates useful in making chromans, especially vitamin E in racemic or optically active forms.

Abstract: Novel pyrimidinedicarbamates of the formula ##STR1## wherein R is lower alkyl or (lower alkyloxy)-(lower alkyl) and X is a leaving group,can be manufactured by carbamoylating the corresponding free diamines. They are valuable intermediates and can be used, for example, for the manufacture of corresponding oxadiazolopyrimidines of the formula ##STR2## and pharmaceutically acceptable salts thereof. The latter have valuable long-lasting vasodilating and/or bloodpressure lowering properties and are accordingly suitable especially for the treatment of vascular-conditioned hypertensions or as vasodilators in the case of peripheral blood supply disorders.

Abstract: This invention relates to a process for encapsulation, and particularly to the production of small or minute capsules constituted by a skin or thin wall of polymeric material e.g., polyurea, polyamide, polysulfonamide, polyester, polycarbonate, or polyurethane, which involves first providing an aqueous solution (continuous phase liquid) containing an emulsifier selected from the group consisting of sulfonated napthalene formaldehyde condensates, sulfonated polystyrenes derivatives and functionalized oligomers. A discontinuous (immiscible or organic) phase liquid containing a water-immiscible material which is the material to be encapsulated, plus a first shell wall component; is dispersed in the aqueous liquid to form an oil-in-water emulsion. The second shell wall component is added to the oil-in-water emulsion whereupon the first shell wall component reacts with the second shell wall component to form a solid polycondensate shell wall about the material to be encapsulated.

Abstract: The present invention is directed to water-soluble film comprising:______________________________________ Component % By Weight ______________________________________ Polyvinyl Alcohol 40-75 Polyvinyl Pyrrolidone 7.5-43 Ethoxylated Alkyphenol 7-20 Polyhydric Alcohol 7-20 ______________________________________The cold water-soluble packaging films formed from the compositions of this invention are useful for packaging of agricultural chemicals which are in granule or dust form. By containing such water dispersable granule or dust agricultural chemicals in water-soluble bag films of this invention, one is able to avoid the problem of dust which may be irritating and/or toxic to the user. Specific examples of agricultural chemicals which are usually packaged in pre-measured portions in the water-soluble films of the present invention are insecticides, herbicides, nematocides, fungicides, plant growth regulants and herbicidal antidotes.

Abstract: Derivatives of 2-imino-1,3-dithiolane, 1,3-dithiole, 1,3-dithiane, 1,3-dithietane and 1,3-oxathiole have been found to reduce herbicidal injury to crop plants due to thiocarbamate and acetanilide herbicides.

Abstract: This invention relates to a process for encapsulation, and particularly to the production of small or minute capsules constituted by a skin or thin wall of polymeric material e.g., polyurea, polyamide, polysulfonamide, polyester, polycarbonate, or polyurethane, which involves first providing an organic liquid (continuous phase liquid) containing an oil soluble alkylated polyvinylpyrrolidone emulsifier A discontinuous (aqueous) phase liquid containing a water-soluble material, which is the material to be encapsulated, plus a first shell wall component; is dispersed in the continuous phase liquid to form a water-in-oil emulsion. The second shell wall component is added to the water-in-oil emulsion whereupon the first shell wall component reacts with the second shell wall component to form a solid polymeric shell wall about the material to be encapsulated. The capsules formed may be directly used as in the form of an organic suspension, i.e., a suspension of microcapsules in the organic liquid.